Wednesday, July 8, 2026

Patent intelligence · US

US 12377151

Immobilized endoglycosidase fusion protein and use thereof

granted A61KA61K2039/505A61K47/22A61K47/26
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 19
Applicant portfolio 36
Patent details — US 12377151
Jurisdiction
US
Status
granted
Grant date
Aug 5, 2025
Expiration
Jul 31, 2045
Claims
17
CPC classes
A61K, A61K2039/505, A61K47/22, A61K47/26
View on Google Patents ↗

Quick answer

US 12377151 (Immobilized endoglycosidase fusion protein and use thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K2039/505, A61K47/22, A61K47/26, A61K47/545, A61K47/549

More from GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12391720

    Salts and polymorphs of cethromycin for the treatment of disease

    AliquantumRx, Inc. · Expires Aug 14, 2045

    granted
  2. US 12370266

    Polymer composite nanomaterial encapsulation system

    Core Quantum, Inc. · Expires Jul 24, 2045

    granted
  3. US 12318457

    Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Expires May 29, 2045

    granted
  4. US 12312377

    Biconjugatable labels and methods of use

    Quantum-Si Incorporated · Expires May 22, 2045

    granted
  5. US 12195454

    Compounds for imaging tau proteins that accumulate in the brain

    National Institutes for Quantum and Radiological Science and Technology · Expires Jan 9, 2045

    granted
  6. US 12102694

    Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus

    NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY · Expires Sep 26, 2044

    granted
  7. US 11999748

    Exatecan derivatives, linker-payloads, and conjugates and thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 12377151?

US 12377151 (Immobilized endoglycosidase fusion protein and use thereof) is held by GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12377151?

GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.

When does US 12377151 expire?

Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.